Answers are grounded in this paper and cite their sources.
Spasmolytic polypeptide-expressing metaplasia (SPEM) is a common, biologically heterogeneous metaplastic phenotype arising in the gastric corpus after oxyntic gland injury.Acute injury-associated SPEM is usually transient and reversible, whereas persistent inflammatory or oncogenic stimulation can result in SPEM with sustained proliferative activity, intestinal differentiation, incomplete intestinal metaplasia, dysplasia, and molecular alterations associated with neoplastic progression.These features identify proliferative SPEM as a progression-associated subset with greater relevance to gastric carcinogenesis.The cellular origin of SPEM remains unresolved and varies among experimental models.Lineage-tracing studies support contributions from corpus isthmus stem/progenitor cells, chief-cell-labeled populations, and the mucous neck-chief transitional lineage.Most of the related lineage-tracing and mechanistic evidence has been derived using mouse models, whereas clinicopathological and molecular associations have been primarily demonstrated via human studies.SPEM is not an obligatory intermediate in gastric carcinogenesis, and its neoplastic potential is linked to particular proliferative metaplastic populations and accompanying stem/progenitor-cell alterations.Reproducible pathological and molecular criteria and prospective human validation are required to establish the value of proliferative SPEM for risk stratification and surveillance.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: